Meeder Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Meeder Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,362	Closed	-$22K	–	2608
2021 Q1	$22K	Buy	+1,362	New	+$26.2K	﹤0.01%	1375
2020 Q2	–	Sell	-4,725	Closed	-$23K	–	2323
2020 Q1	$23K	Buy	4,725 +3,625	+330%	+$17.9K	﹤0.01%	1189
2019 Q4	$4K	Hold	1,100	–	–	﹤0.01%	1853
2019 Q3	$3K	Buy	1,100 +192	+21%	+$858	﹤0.01%	1887
2019 Q2	$4K	Buy	908 +174	+24%	+$644	﹤0.01%	1729
2019 Q1	$3K	Sell	734 -1,335	-65%	-$5.37K	﹤0.01%	1505
2018 Q4	$8K	Buy	2,069 +1,462	+241%	+$8.06K	﹤0.01%	1308
2018 Q3	$4K	Buy	+607	New	+$3.81K	﹤0.01%	1372
2017 Q2	–	Sell	-756	Closed	-$7K	–	1808
2017 Q1	$7K	Sell	756 -1,132	-60%	-$9.43K	﹤0.01%	956
2016 Q4	$16K	Buy	1,888 +1,388	+278%	+$10.8K	﹤0.01%	683
2016 Q3	$3K	Buy	+500	New	+$3.05K	﹤0.01%	726

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Meeder Asset Management's OCUL Position: Q2 2021 in Review

Meeder Asset Management sold out of Ocular Therapeutix (OCUL) in Q2 2021, closing a stake of 1,362 shares — an estimated $22K sold.

Meeder Asset Management first reported a position in OCUL in Q3 2016 and held it in 11 quarters. The position peaked at $23K in Q1 2020. 149 funds tracked by Wall St. Rank hold OCUL as of Q2 2021.

Meeder Asset Management reported no remaining Ocular Therapeutix position as of Q2 2021 after selling out during the quarter.
Meeder Asset Management sold 1,362 Ocular Therapeutix shares in Q2 2021, an estimated $22K.
Meeder Asset Management first reported a position in Ocular Therapeutix in Q3 2016 and held it in 11 quarters.
Meeder Asset Management's Ocular Therapeutix position peaked at $23K in Q1 2020.
149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2021.

Based on Meeder Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.